From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Target | Antibody Product | Company/Authors | Reference |
---|---|---|---|
TGF-β × PD-L1 | M7824 | Merck KGaA | [278] |
YM101 | Wuhan YZY Biopharma | [279] | |
SHR-1701 | Hengrui Pharmaceuticals | [280] | |
CTLA-4 × PD-L1 | KN046 | Alphamab Oncology | [281] |
CTLA-4 × PD-1 | MGD019 | MacroGenics | [282] |
MEDI5752 | AstraZeneca | [283] | |
LAG-3 × PD-L1 | IBI323 | Innovent Biologics | [284] |
LAG-3 × PD-1 | Tebotelimab | MacroGenics | [285] |
TIM-3 × PD-L1 | LY3415244 | Eli Lilly | [286] |
TIGIT×PD-L1 | Not given | Novamab Biopharmaceuticals | [287] |
4-1BB × PD-L1 | MCLA-145 | Merus and Incyte | [288] |
ABL503 | ABL Bio | [289] | |
PM1003 | Biotheus | [290] | |
CD27 × PD-L1 | CDX-527 | Celldex Therapeutics | [291] |
c-Met×PD-1 | Not given | Yuan et. al | [292] |
Not given | Hou et. al | [293] | |
Not given | Wu et. al | [294] | |
Not given | Sun et. al | [295] | |
EGFR×PD-L1 | Not given | Koopmans et. al | [296] |
PD-1 × PD-L1 | LY3434172 | Eli Lilly | [297] |
CD47 × PD-L1 | IBI322 | Innovent Biologics | [298] |